{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:23:54Z","timestamp":1762608234137,"version":"3.37.3"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Ensign Endowment for Gynecologic Cancer Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1245\/s10434-021-09900-4","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T22:02:39Z","timestamp":1617314559000},"page":"7591-7603","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Association Between Adjuvant Therapy and Survival in Stage II\u2013III Endometrial Cancer: Influence of Malignant Peritoneal Cytology"],"prefix":"10.1245","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6232-8701","authenticated-orcid":false,"given":"Koji","family":"Matsuo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Nusbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynda D.","family":"Roman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason D.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Harter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Klar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"issue":"2","key":"9900_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87\u2013108.","journal-title":"CA Cancer J Clin"},{"issue":"9823","key":"9900_CR2","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(12)60442-5","volume":"379","author":"JD Wright","year":"2012","unstructured":"Wright JD, Barrena Medel NI, Sehouli J, Fujiwara K, Herzog TJ. Contemporary management of endometrial cancer. Lancet. 2012;379(9823):1352\u201360.","journal-title":"Lancet"},{"issue":"10023","key":"9900_CR3","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(15)00130-0","volume":"387","author":"P Morice","year":"2016","unstructured":"Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet. 2016;387(10023):1094\u2013108.","journal-title":"Lancet"},{"key":"9900_CR4","unstructured":"Uterine. Neoplasms. NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network. https:\/\/www.nccn.org\/professionals\/physician_gls\/. Accessed 23 Jul 2020."},{"issue":"1","key":"9900_CR5","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.3802\/jgo.2020.31.e18","volume":"31","author":"W Yamagami","year":"2020","unstructured":"Yamagami W, Mikami M, Nagase S, et al. Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasms. J Gynecol Oncol. 2020;31(1):e18.","journal-title":"J Gynecol Oncol"},{"issue":"1","key":"9900_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/annonc\/mdv484","volume":"27","author":"N Colombo","year":"2016","unstructured":"Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016;27(1):16\u201341.","journal-title":"Ann Oncol."},{"key":"9900_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ejca.2020.03.031","volume":"133","author":"K Matsuo","year":"2020","unstructured":"Matsuo K, Matsuzaki S, Nusbaum DJ, et al. Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer. Eur J Cancer. 2020;133:33\u201346.","journal-title":"Eur J Cancer"},{"issue":"2","key":"9900_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ygyno.2018.02.012","volume":"149","author":"K Matsuo","year":"2018","unstructured":"Matsuo K, Yabuno A, Hom MS, et al. Significance of abnormal peritoneal cytology on survival of women with stage I\u2013II endometrioid endometrial cancer. Gynecol Oncol. 2018;149(2):301\u20139.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"9900_CR9","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.3802\/jgo.2018.29.e34","volume":"29","author":"K Tate","year":"2018","unstructured":"Tate K, Yoshida H, Ishikawa M, et al. Prognostic factors for patients with early-stage uterine serous carcinoma without adjuvant therapy. J Gynecol Oncol. 2018;29(3):e34.","journal-title":"J Gynecol Oncol"},{"issue":"3","key":"9900_CR10","doi-asserted-by":"publisher","first-page":"329.e321","DOI":"10.1016\/j.ajog.2017.11.601","volume":"218","author":"BL Seagle","year":"2018","unstructured":"Seagle BL, Alexander AL, Lantsman T, Shahabi S. Prognosis and treatment of positive peritoneal cytology in early endometrial cancer: matched cohort analyses from the National Cancer Database. Am J Obstet Gynecol. 2018;218(3):329.e321-329.e315.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"9900_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3802\/jgo.2014.25.1.30","volume":"25","author":"UM Haltia","year":"2014","unstructured":"Haltia UM, B\u00fctzow R, Leminen A, Loukovaara M. FIGO 1988 versus 2009 staging for endometrial carcinoma: a comparative study on prediction of survival and stage distribution according to histologic subtype. J Gynecol Oncol. 2014;25(1):30\u20135.","journal-title":"J Gynecol Oncol"},{"issue":"1","key":"9900_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ygyno.2012.09.026","volume":"128","author":"G Garg","year":"2013","unstructured":"Garg G, Gao F, Wright JD, Hagemann AR, Mutch DG, Powell MA. Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer. Gynecol Oncol. 2013;128(1):77\u201382.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"9900_CR13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/AOG.0b013e3181a94568","volume":"114","author":"S Bansal","year":"2009","unstructured":"Bansal S, Buck AM, Herzog TJ, Deutsch I, Burke WM, Wright JD. Stage IIIA endometrial carcinoma: outcome and predictors of survival. Obstet Gynecol. 2009;114(1):100\u20135.","journal-title":"Obstet Gynecol."},{"issue":"2","key":"9900_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ygyno.2006.08.027","volume":"104","author":"LJ Havrilesky","year":"2007","unstructured":"Havrilesky LJ, Cragun JM, Calingaert B, et al. The prognostic significance of positive peritoneal cytology and adnexal\/serosal metastasis in stage IIIA endometrial cancer. Gynecol Oncol. 2007;104(2):401\u20135.","journal-title":"Gynecol Oncol."},{"issue":"1","key":"9900_CR15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ygyno.2006.03.003","volume":"103","author":"Y Saga","year":"2006","unstructured":"Saga Y, Imai M, Jobo T, et al. Is peritoneal cytology a prognostic factor of endometrial cancer confined to the uterus? Gynecol Oncol. 2006;103(1):277\u201380.","journal-title":"Gynecol Oncol."},{"issue":"1","key":"9900_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ygyno.2020.07.010","volume":"159","author":"K Matsuo","year":"2020","unstructured":"Matsuo K, Nusbaum DJ, Matsuzaki S, et al. Malignant peritoneal cytology and increased mortality risk in stage I non-endometrioid endometrial cancer. Gynecol Oncol. 2020;159(1):43\u201351.","journal-title":"Gynecol Oncol."},{"issue":"8","key":"9900_CR17","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1136\/ijgc-2019-000643","volume":"29","author":"I Kahramanoglu","year":"2019","unstructured":"Kahramanoglu I, Meydanli MM, Taranenka S, et al. SATEN III-splitting adjuvant treatment of stage III ENdometrial cancers: an international, multicenter study. Int J Gynecol Cancer. 2019;29(8):1271\u20139.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"9900_CR18","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ygyno.2014.05.013","volume":"134","author":"SA Milgrom","year":"2014","unstructured":"Milgrom SA, Kollmeier MA, Abu-Rustum NR, O\u2019Cearbhaill RE, Barakat RR, Alektiar KM. Quantifying the risk of recurrence and death in stage III (FIGO 2009) endometrial cancer. Gynecol Oncol. 2014;134(2):297\u2013301.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"9900_CR19","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1097\/IGC.0b013e3182978328","volume":"23","author":"S Kuku","year":"2013","unstructured":"Kuku S, Williams M, McCormack M. Adjuvant therapy in stage III endometrial cancer: treatment outcomes and survival. A single-institution retrospective study. Int J Gynecol Cancer. 2013;23(6):1056\u201364.","journal-title":"Int J Gynecol Cancer"},{"key":"9900_CR20","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. http:\/\/seer.cancer.gov\/. Accessed 23 Jul 2020."},{"issue":"11","key":"9900_CR21","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1002\/1097-0142(19951201)76:11<2343::AID-CNCR2820761124>3.0.CO;2-#","volume":"76","author":"C Zippin","year":"1995","unstructured":"Zippin C, Lum D, Hankey BF. Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer. 1995;76(11):2343\u201350.","journal-title":"Cancer."},{"key":"9900_CR22","unstructured":"National Cancer Registrars Association. http:\/\/www.ncra-usa.org\/. Accessed 23 Jul 2020."},{"key":"9900_CR23","unstructured":"CorpusCarcinoma. CS Site-Specific Factor 2 Peritoneal Cytology. http:\/\/web2.facs.org\/cstage0205\/corpuscarcinoma\/CorpusCarcinoma_kpo.html. Accessed 23 Jul 2020."},{"issue":"Suppl 23","key":"9900_CR24","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1002\/cncr.29054","volume":"120","author":"PM Jamison","year":"2014","unstructured":"Jamison PM, Altekruse SF, Chang JT, et al. Site-specific factors for cancer of the corpus uteri from SEER registries: collaborative stage data collection system, version 1 and version 2. Cancer. 2014;120(Suppl 23):3836\u201345.","journal-title":"Cancer"},{"key":"9900_CR25","unstructured":"International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3). World Health Organization. Available at: https:\/\/www.who.int\/classifications\/icd\/adaptations\/oncology\/en\/. Accessed 23 Jul 2020."},{"key":"9900_CR26","unstructured":"American. Joint Committee on Cancer. https:\/\/cancerstaging.org\/Pages\/default.aspx. Accessed 23 Jul 2020."},{"key":"9900_CR27","volume-title":"Gynecologic Oncology Group surgical procedures manual","author":"CW Whitney","year":"2009","unstructured":"Whitney CW, Spirtos N. Gynecologic Oncology Group surgical procedures manual. Philadelphia, PA: Gynecologic Oncology Group; 2009."},{"issue":"28","key":"9900_CR28","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661\u201379.","journal-title":"Stat Med"},{"key":"9900_CR29","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. 2nd edn. Hillsdale, NJ: Erlbaum; 1988.","edition":"2"},{"issue":"6","key":"9900_CR30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.jasc.2020.05.015","volume":"9","author":"D Pinto","year":"2020","unstructured":"Pinto D, Chandra A, Crothers BA, Kurtycz DFI, Schmitt F. The international system for reporting serous fluid cytopathology-diagnostic categories and clinical management. J Am Soc Cytopathol. 2020;9(6):469\u201377.","journal-title":"J Am Soc Cytopathol"},{"issue":"7","key":"9900_CR31","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1002\/sim.6782","volume":"35","author":"M Pavlou","year":"2016","unstructured":"Pavlou M, Ambler G, Seaman S, De Iorio M, Omar RZ. Review and evaluation of penalised regression methods for risk prediction in low-dimensional data with few events. Stat Med. 2016;35(7):1159\u201377.","journal-title":"Stat Med"},{"key":"9900_CR32","unstructured":"National. Cancer Institute. Joinpoint trend analysis software. https:\/\/surveillance.cancer.gov\/joinpoint\/. Accessed 19 Jul 2020."},{"issue":"6","key":"9900_CR33","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","volume":"133","author":"PC Austin","year":"2016","unstructured":"Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133(6):601\u20139.","journal-title":"Circulation"},{"issue":"7624","key":"9900_CR34","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806\u20138.","journal-title":"BMJ"},{"issue":"1","key":"9900_CR35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/ijc.32872","volume":"147","author":"C Mayo-de-Las-Casas","year":"2020","unstructured":"Mayo-de-Las-Casas C, Velasco A, Sanchez D, et al. Detection of somatic mutations in peritoneal lavages and plasma of endometrial cancer patients: a proof-of-concept study. Int J Cancer. 2020;147(1):277\u201384.","journal-title":"Int J Cancer"},{"issue":"4","key":"9900_CR36","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.fertnstert.2011.07.1146","volume":"96","author":"YN Chang","year":"2011","unstructured":"Chang YN, Zhang Y, Wang YJ, Wang LP, Duan H. Effect of hysteroscopy on the peritoneal dissemination of endometrial cancer cells: a meta-analysis. Fertil Steril. 2011;96(4):957\u201361.","journal-title":"Fertil Steril"},{"issue":"1","key":"9900_CR37","doi-asserted-by":"publisher","first-page":"65 e61","DOI":"10.1016\/j.ajog.2020.07.025","volume":"224","author":"P Padilla-Iserte","year":"2021","unstructured":"Padilla-Iserte P, Lago V, Tauste C, et al. Impact of uterine manipulator on oncological outcome in endometrial cancer surgery. Am J Obstet Gynecol. 2021;224(1):65 e61-65 e11.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"9900_CR38","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","volume":"19","author":"SM de Boer","year":"2018","unstructured":"de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(3):295\u2013309.","journal-title":"Lancet Oncol."},{"issue":"9","key":"9900_CR39","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S1470-2045(19)30395-X","volume":"20","author":"SM de Boer","year":"2019","unstructured":"de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019;20(9):1273\u201385.","journal-title":"Lancet Oncol."},{"issue":"24","key":"9900_CR40","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","volume":"380","author":"D Matei","year":"2019","unstructured":"Matei D, Filiaci V, Randall ME, et al. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med. 2019;380(24):2317\u201326.","journal-title":"N Engl J Med"},{"key":"9900_CR41","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ejca.2020.04.012","volume":"133","author":"WJ van Weelden","year":"2020","unstructured":"van Weelden WJ, Reijnen C, Eggink FA, et al. Impact of different adjuvant treatment approaches on survival in stage III endometrial cancer: a population-based study. Eur J Cancer. 2020;133:104\u201311.","journal-title":"Eur J Cancer"},{"issue":"1","key":"9900_CR42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/AOG.0000000000003287","volume":"134","author":"S Syeda","year":"2019","unstructured":"Syeda S, Chen L, Hou JY, et al. Chemotherapy, radiation, or combination therapy for stage III uterine cancer. Obstet Gynecol. 2019;134(1):17\u201329.","journal-title":"Obstet Gynecol"},{"issue":"9","key":"9900_CR43","doi-asserted-by":"publisher","first-page":"djv158","DOI":"10.1093\/jnci\/djv158","volume":"107","author":"AS Felix","year":"2015","unstructured":"Felix AS, Brinton LA, McMeekin DS, et al. Relationships of tubal ligation to endometrial carcinoma stage and mortality in the NRG Oncology\/Gynecologic Oncology Group 210 Trial. J Natl Cancer Inst. 2015;107(9):djv158.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"9900_CR44","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1093\/annonc\/mdx753","volume":"29","author":"SM de Boer","year":"2018","unstructured":"de Boer SM, Wortman BG, Bosse T, et al. Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer. Ann Oncol. 2018;29(2):424\u201330.","journal-title":"Ann Oncol"},{"issue":"6","key":"9900_CR45","doi-asserted-by":"publisher","first-page":"594 e591","DOI":"10.1016\/j.ajog.2017.02.021","volume":"216","author":"JD Wright","year":"2017","unstructured":"Wright JD, Cham S, Chen L, et al. Utilization of sentinel lymph node biopsy for uterine cancer. Am J Obstet Gynecol. 2017;216(6):594 e591-594 e513.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"9900_CR46","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ajog.2020.10.045","volume":"224","author":"K Matsuo","year":"2021","unstructured":"Matsuo K, Matsuzaki S, Roman LD, Klar M, Wright JD. Proposal of an endometrial cancer staging schema with stage-specific incorporation of malignant peritoneal cytology. Am J Obstet Gynecol. 2021;224(3):319\u201321.","journal-title":"Am J Obstet Gynecol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-09900-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-021-09900-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-09900-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T20:10:06Z","timestamp":1634328606000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-021-09900-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["9900"],"URL":"https:\/\/doi.org\/10.1245\/s10434-021-09900-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"type":"print","value":"1068-9265"},{"type":"electronic","value":"1534-4681"}],"subject":[],"published":{"date-parts":[[2021,4,1]]},"assertion":[{"value":"18 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The following disclosures are declared, outside the submitted work: Jason\u00a0D.\u00a0Wright is a consultant for Clovis Oncology and has undertaken research funding for Merck. Lynda\u00a0D.\u00a0Roman is a consultant for Quantgene. Koji\u00a0Matsuo has received honorarium from Chugai, textbook editorial expenses from Springer, and investigator meeting attendance expenses from VBL therapeutics. Shinya\u00a0Matsuzaki has received research funding from MSD. Philipp\u00a0Harter has received personal fees, non-financial support, honoraria for lectures, advisory board fees, and travel support from AstraZeneca and Roche; non-financial support and travel support from Medac; personal fees, honoraria for lectures, and advisory board fees from Tesaro and PharmaMar; personal fees and honoraria for advisory board participation from Clovis and Lilly; personal fees and honoraria for lectures from Stryker; and personal fees and honoraria for advisory board participation from Immunogen. Maximilian\u00a0Klar has received advisory board fees from Tesaro and GSK. David J. Nusbaum has no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}